Complications after blood components still constitute an important clinical problem and serve as limitation of liberal-transfusion strategy. the aim of the study was to present the 5-year incidence of early blood transfusions complications and to assess their relation to the type of the transfused blood components. Material and methods. 58,505 transfusions of blood components performed in the years 2006-2010 were retrospectively analyzed. Data concerning the amount of the transfused blood components and the numbers of adverse transfusion reactions reported to the Regional Blood Donation and Treatment Center (RBDTC) was collected. Results. 95 adverse transfusion reactions were reportedto RBDTC 0.16% of alldonations (95/58 505) -58 after PRBC transfusions, 28 after platelet concentrate transfusions and 9 after FFP transfusion. Febrile nonhemolytic and allergic reactions constitute respectively 36.8% and 30.5% of all complications. conclusion. Nonhemolyticand allergic reactions are the most common complications of blood components transfusion and they are more common after platelet concentrate transfusions in comparison to PRBC and FFP donations.
In the last decades new screening procedures and tests were implemented to improve the safety of blood transfusions. However because of the most recent risks and threats, a zero-risk blood supply is still nearly impossible (1) . Transfusion complications can be categorized into infectious and noninfectious: immunologic and non-immunologic. The risk of infections cannot be eliminated completely, because of window periods during which pathogens are not detectable and because of the risk of new pathogens emerging (2) . Currently, infectious agents for which donated blood can be tested include hepatitis B (HBV) and C (HBC), HIV-1 and -2, human T-cell lymphotropic virus (HTLV)-1 and -2, West Nile virus, Treponema pallidum (syphilis), Trypanosoma cruzi (Chagas disease), and cytomegalovirus (CMV). Other infectious threats include Babesia, Plasmodiums (malaria), prions (variant CreutzfeldtJakob disease), hepatitis A virus and human herpes virus 8. Although various methods of pathogen inactivation are under investigation their efficacy and effect on the quality of blood products need to be determined (3) .
Bacterial infections (TTBI) also create an important issue in blood transfusions.The incidence of TTBI is higher than the incidence of transfusion transmitted viral infection (4, 5, 6) . Many studies showed that the most com-mon bacterial contaminants in case of red blood cell concentrates (RBCC) are: Yersinia enterocolitica (51% of all bacterial infections), Pseudomonas fluorescens (26.5%), Pseudomonas putida (4.1%) and Treponema palidum (4.1%) (7, 8) . Different bacteria are responsible for platelet concentrates (PC) contamination: Corynebacterium sp. (36.5%) Staphylococcus epidermidis (25%), Salmonellscholeraesuis (13.5%), Serratia marcescens (9.6%), Staphylococcus aureus, Bacillus cereus and Streptococcus viridans group (7) .
It was estimated that in the United States bacterial contamination of transfusion products is the second most common cause of death from transfusion (mortality rates from 1/20,000 to 1/85,000 donor exposures) (8) . However, due to the recent strategies in blood donation and newest technologies in pathogens inactivation the rate of transfusion transmitted bacterial infection has decreased.
According to some studies, risks of infection per blood unit range from 1:100,000 to 1:400,000 for HBV, 1:1,600,000 to 1:3,100,000 for HCV, 1:1,400,000 to 1: 4,700,000 for HIV, 1:500,000 to 1: 3,000,000 for HTLV, and 1:4,000,000 for malaria (9) . Bacterial contamination is estimated for approximately 1:60,000 units of RBCC and is more common in apheresis platelets (1:8000) (10). According to the UK's Serious Hazards of Transfusion (SHOT) 2010 report, no confirmed case of transfusion-transmitted infection was detected. However, noninfectious risks and complications of blood transfusion have taken the lead (11) .
Noninfectious risks of transfusion are far more common and usually more severe. They can be grouped under immunologic (hemolytic and non-hemolytic transfusion reactions, allergic and anaphylactic reactions, multiple organ failure, immunomodulation, HLA alloimmunization, autoimmunization RBC, transfusion-associated graft versus host disease,transfusion-associated acute lung injury) and non-immunologic (febrile non-hemolytic transfusion reactions RBC storage lesions,circulatory overload, iron overload, metabolic disturbances) complications.
The aim of the study was to presentthe 5-year incidence of early blood transfusions complications and to assess their relation to the type of the transfused blood components in the Copernicus Memorial Hospital in Łódź. A criterion of hemoglobin concentration of less than 6 g/dL in combination with symptoms of severe hemorrhagic diathesis was adopted as the indications for transfusion of packed red blood cells (PRBC) in patients with chronic diseases in the study. In the event of a sudden loss of 1500-2000 mL of blood, a PRBC transfusion was indicated in patients with signs of cardiac decompensation without prior anemia. The loss of 40% (> 2000 mL) of circulating blood volume was treated as an absolute indication for rapid transfusion of PRBC preparations. For platelet preparations, the indications for administration was platelet count of less than 20,000/µL in patients with acute leukemia and those after transplantation of hematopoietic stem cells, with concomitant bleeding or below 10,000/µL in stable patients. Transfusion of fresh frozen plasma (FFP) was performed in patients with coagulation disorders and those with symptoms of bleeding disorders. The final decision on a particular blood component transfusion was taken on the basis of the patient's general state, clinical symptoms and the patient's adaptation to the decreased values of blood counts.
MATERIAL AND METHODS
All the transfused PRBC were without buffy coat and all platelet concentrates were filtered-according to RBDTC issues only buffycoat deprived PRBC preparations and platelet concentrates subjected to previous filtration are donated. In the Department of Hematology, in immunosuppressed and immunocom-promised recipients, most cell concentrates were irradiated in order to minimize the risk of TA-GvHD.
Of the 58,505 transfused blood components, 68.96% (40 348/58 505) were PRBC and 13.22% (7 734/58 505) were platelet concentrate preparations. Platelet preparations were obtained with two methods -by apheresis or from buffy coat with ORBISAK apparatus. The remaining 17.82% (10 423/58 505) were plasma transfusions.
Inthe event of an adverse transfusion reaction, a procedure in accordance with thehospital standards designed on the basis of the Minister of Health Regulation was undertaken -documentation and patient blood sampleas well as the transfused blood sample were provided to the Regional Centre. Among the adverse transfusion reactions, only early reactions that can be detected during hospitalization, were noted.
Statistical Analysis
To seek the relationship between the data, chi 2 test of independence was used. The threshold for statistical significance was the value of p ≤0.05.
RESULTS
Annually,approximately 9000 units of PRBC, 2,000 platelet donations and 3,000 FFP donations were transfused in the hospital. On average, 20 adverse transfusion reactions were reported each year. Five-year analysis of data on early transfusion complications showed that in the years 2006-2010, 95 adverse transfusion reactions were reported to RBDTC -58 after PRBC transfusions, 28 after platelet concentrate transfusions and 9 after FFP transfusion. In relation to the total number of the transfused blood components, adverse reactions were reported after 0.16% of all donations (95/58 505). Most complications occurred after platelet concentration transfusions and concerned approximately 0.36% of cases. Although complications after PRBC transfusions occurred only in 0.14% of cases, they constituted the largest group of reactions reported to RB-DTC due to the overall number of transfusions -PRBC were transfused 5 times more often than platelet concentrates. There was a statistically significant correlation between the frequency of early transfusion complications and the type of blood component used in the fiveyear observation period. Significantly higher incidence of adverse transfusion reactions was observed after platelet preparations than for PRBC (p <0.001) and FFP transfusions (p <0.001), as shown in tab. 1.
From early adverse transfusion reactions we observed: febrile non-hemolytic reactions, allergic reactions, anti-HLA antibodies production, symptoms such as pulmonary edema, shortness of breath, heart failure, transfusion of AB0-incompatible blood components and in one patient we observed symptoms, suggesting bacterial complication. After PRBC transfusions, the most common complications (22 cases) were febrile non-hemolytic reactions. More rarely the cause of adverse PRBC reaction were anti-HLA antibodies produced by the patient (12 cases) and allergic reactions (12 cases). Platelet concentration transfusions caused allergic reactions more often (12 cases) than the febrile non-hemolytic reactions (11 cases). Only in 4 cases the transfusion reaction involved the production of anti-HLA antibodies in the recipient. Allergic reactions were the most common cause of reactions after FFP transfusions and occurred in 5 patients. There was one case of transfusion of an AB0-incompatible blood component. FFP group 0 was transfused to a group B recipient. There were no symptoms associated with the effect of the transfused anti-B antibodies to the recipient red blood cells. Statistical analysis of the incidence of complications in relation to the type of blood components showed that platelet concentration transfusions were associated with a significantly higher risk of developing a febrile non-hemolytic reaction and allergic reaction, as compared with PRBC (p<0.01 and p<0.001) and FFP transfusions (p<0.001 and p<0.05). Platelet concentration transfusions significantly more often caused HLA antibodies production, as compared to FFP administration (p<0.05) (tab. More than 52% of FFP units transfused in the hospital were administered to recipients from these wards. Nevertheless, adverse reactions occurred in only 20 cases on these wards, which represented approximately 21% of all reported adverse transfusion reactions. In the Department of Intensive Care Medicine and Anesthesiology there was no adverse reaction observed after FFP donations ( fig. 1) .
Statistical analysis disclosed that in departments of Internal Medicine (the Department of Hematology was included in this group) and in Department of Hematology separately, complications were observed significantly more often than in surgical and oncological departments (p<0.001 and p<0.05). The frequency of adverse transfusion reactions in departments of Internal Medicine and the Department of Hematology was similar (p>0.05). There was a significantly higher incidence of adverse reactions in patients treated in the Department of Oncological Surgery than in other surgical departments altogether (p<0.05). Complications after PRBC donations occurred significantly more often in departments of Internal Medicine (with Department of Hematology included to this group) and in the Department of Hematology separately in comparison to surgical departments (p<0.01 and p<0.01). In all departments, except for the Department of Intensive Care Medicine and Anesthesiology, adverse transfusion reactions after FFP donations were observed with similar frequency (p<0.05). No statistical difference was observed among departments in frequency of complications after platelet concentrate (p>0.05) (tab. 3).
DISCUSSION
In recent years a great progress was made in blood components preparation technologies, however, complications after their transfusion still constitute an important clinical problem and serve as limitation of liberal-transfusion strategy. The data from the UK's Serious Hazards of Transfusion (SHOT) (2010) showed that 505 serious complications and events resulting in 4.5 deaths and 35 major morbidities were reported per 1 million units of blood component issued (11) . The report presents a relatively low incidence of complications, however the frequency of unfavorable outcomes associated with allogeneic blood transfusions observed in many studies examining specific groups of patients is much higher (12-23). In the analyzed group of patients the incidence of early adverse transfusion reactions was 0.16%, however it is difficult to interpret this rate and compare it with the values presented in the literature as it depends on the hospital profile, transfusion strategy and reporting programs. Different programs of documenting complications result in the fact that some of them [e.g. transfusion-related acute lung injury (TRALI)] are vastly underdiagnosed and under-reported (24, 25). However as concluded by Shander et al. these statistics provide an overall picture of the prevalence of complications and risks of blood transfusions and their consequences (26).
It was estimated that a single noninfectious complication [eg, transfusion-related acute lung injury (TRALI)] occurs in 1 case per every 5000 units of blood component transfused (25). Febrile non-hemolytic transfusion reaction is known to be the most common cause of transfusion-associated fever and occurs in 0.1% to 1% of RBC transfusions (27). The same observation was made on the basis of our material analysis, as the most common complications were febrile non-hemolytic reactions and allergic reactions, which constituted 35.79% and 30.53% of all noted reactions. Moreover, there was a significantly higher incidence of these (11) . In our material there was one case of transfusion of an AB0-incompatible blood component. FFP group 0 was transfused to a group B recipient. We did not observed any symptoms associated with the effect of the transfused anti-B antibodies to the recipient red blood cells. The only detectable reaction was positive direct antiglobulin test, persisting for several days after the transfusion.
Although non-infectious complications of blood transfusion are considerably more common and according to the SHOT 2010 report no transfusion-transmitted infection was detected, such risk needs to be mentioned. The incidence of bacterial contamination is much higher in case of platelets donations while minimal for RBC units (10). Such complications may result from the fact that the standard procedure for blood preparation cannot eliminate the risk completely, because of pathogens window periods and some new pathogens emerging. In our analysis, we suspected transfusion-transmitted bacterial infection in one patient after PRBC donation.
Complications such as: transfusion-associated acute lung injury (TRALI), post-transfusion purpura, acute hemolytic reactions, anaphylactic shock, septic shock did not occur in our patients. This observation is consistent with the data presented in the literature as such complications are rare: 20 per 1 million units (hemolytic reactions), 5 per million units (TRALI) and nearly zero per million units for the rest (11) .
To sum up, it can be seen from the study that non-hemolytic and allergic reactions are the most common complications of blood components transfusion and they are more common after platelet concentrate transfusions in comparison to PRBC and FFP donations. Although strict procedures are applied during blood donations preparations and transfusions, errors in transfusion and infection complications still serve a problem in clinical practice. We also found that the Department of Hematology is leading in the number oft ransfusions performed, with the highest rate of early adverse transfusion reactions.
